SIRT6 inhibits growth of gastric cancer by inhibiting JAK2/STAT3 pathway

Zhou,Jianmei; Wu,Ang; Yu,Xiaoting; Zhu,Jianwei; Dai,Hui

doi:10.3892/or.2017.5753

SIRT6 inhibits growth of gastric cancer by inhibiting JAK2/STAT3 pathway

Authors:
- Jianmei Zhou
- Ang Wu
- Xiaoting Yu
- Jianwei Zhu
- Hui Dai
View Affiliations

Affiliations: Department of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang 310002, P.R. China, Intensive Care Unit, Hangzhou Cancer Hospital, Hangzhou, Zhejiang 310002, P.R. China, Department of Radiotherapy, Hangzhou Cancer Hospital, Hangzhou, Zhejiang 310002, P.R. China
Published online on: June 27, 2017 https://doi.org/10.3892/or.2017.5753
Pages: 1059-1066

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SIRT6, a member of NAD positivity-dependent class III deacetylase sirtuin family, played versatile roles in human cancers. However, the expression and biological function of SIRT6 in gastric cancer (GC) remain to be investigated. In this study, we found that SIRT6 expression level was decreased in gastric cancer tissues and cell lines. Decreased SIRT6 expression was associated with unfavorable clinical parameters including tumor differentiation, tumor size and TNM stage. Importantly, decreased level of SIRT6 was associated with decreased rate of overall survival (OS) and disease‑free survival (DFS). Functionally, overexpression of SIRT6 in both BGC823 and SGC7901 cells inhibited cell viability and proliferation of GC cells. Furthermore, overexpression of SIRT6 in both BGC823 and SGC7901 cells prevented the cell cycle progress and increased cell apoptosis. In vivo experiments demonstrated that forced expression of SIRT6 in SGC-7901 cells inhibited the growth of SGC7901 cells in nude mice. Furthermore, the IHC staining for GC tissues showed that expression level of SIRT6 was decreased in GC tissues while the expression level of p-STAT3 was increased in GC tissues. GC tissues with high SIRT6 level showed significantly decreased level of p-STAT3. Mechanically, we demonstrated that SIRT6 blocked the activation of JAK2/STAT3 and inhibited the expression of cyclin D1 and Bcl2 which were downstream targets of JAK2/STAT3 pathway. Taken together, this study indicates that SIRT6 inhibits the growth of gastric cancer by inhibiting JAK2/STAT3 pathway.

View Figures

View References

1	Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI
2	Saragoni L, Morgagni P, Gardini A, Marfisi C, Vittimberga G, Garcea D and Scarpi E: Early gastric cancer: Diagnosis, staging, and clinical impact. Evaluation of 530 patients. New elements for an updated definition and classification. Gastric Cancer. 16:549–554. 2013. View Article : Google Scholar : PubMed/NCBI
3	Carcas LP: Gastric cancer review. J Carcinog. 13:142014. View Article : Google Scholar : PubMed/NCBI
4	Gertler AA and Cohen HY: SIRT6, a protein with many faces. Biogerontology. 14:629–639. 2013. View Article : Google Scholar : PubMed/NCBI
5	Pan PW, Feldman JL, Devries MK, Dong A, Edwards AM and Denu JM: Structure and biochemical functions of SIRT6. J Biol Chem. 286:14575–14587. 2011. View Article : Google Scholar : PubMed/NCBI
6	Houtkooper RH, Pirinen E and Auwerx J: Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 13:225–238. 2012.PubMed/NCBI
7	Xiao C, Kim H-S, Lahusen T, Wang RH, Xu X, Gavrilova O, Jou W, Gius D and Deng CX: SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J Biol Chem. 285:36776–36784. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kanfi Y, Peshti V, Gil R, Naiman S, Nahum L, Levin E, Kronfeld-Schor N and Cohen HY: SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell. 9:162–173. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sundaresan NR, Vasudevan P, Zhong L, Kim G, Samant S, Parekh V, Pillai VB, Ravindra PV, Gupta M, Jeevanandam V, et al: The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med. 18:1643–1650. 2012. View Article : Google Scholar : PubMed/NCBI
10	Xiao C, Wang R-H, Lahusen TJ, Park O, Bertola A, Maruyama T, Reynolds D, Chen Q, Xu X, Young HA, et al: Progression of chronic liver inflammation and fibrosis driven by activation of c-JUN signaling in Sirt6 mutant mice. J Biol Chem. 287:41903–41913. 2012. View Article : Google Scholar : PubMed/NCBI
11	Mao Z, Tian X, Van Meter M, Ke Z, Gorbunova V and Seluanov A: Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence. Proc Natl Acad Sci USA. 109:11800–11805. 2012. View Article : Google Scholar : PubMed/NCBI
12	Sebastián C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, et al: The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
13	Zhang Z-G and Qin C-Y: Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal-regulated kinase signaling pathway. Mol Med Rep. 9:882–888. 2014.PubMed/NCBI
14	Lu C-T, Hsu C-M, Lin P-M, Lai CC, Lin HC, Yang CH, Hsiao HH, Liu YC, Lin HY, Lin SF, et al: The potential of SIRT6 and SIRT7 as circulating markers for head and neck squamous cell carcinoma. Anticancer Res. 34:7137–7143. 2014.PubMed/NCBI
15	Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong S, et al: SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. 34:1476–1486. 2013. View Article : Google Scholar : PubMed/NCBI
16	Liu Y, Xie QR, Wang B, Shao J, Zhang T, Liu T, Huang G and Xia W: Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics. Protein Cell. 4:702–710. 2013. View Article : Google Scholar : PubMed/NCBI
17	Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, Seluanov A and Gorbunova V: SIRT6 promotes DNA repair under stress by activating PARP1. Science. 332:1443–1446. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chiang W-C, Tishkoff DX, Yang B, Wilson-Grady J, Yu X, Mazer T, Eckersdorff M, Gygi SP, Lombard DB and Hsu AL: C. elegans SIRT6/7 homolog SIR-2.4 promotes DAF-16 relocalization and function during stress. PLoS Genet. 8:e10029482012. View Article : Google Scholar : PubMed/NCBI
19	Roth M and Chen WY: Sorting out functions of sirtuins in cancer. Oncogene. 33:1609–1620. 2014. View Article : Google Scholar : PubMed/NCBI
20	Van Meter M, Mao Z, Gorbunova V and Seluanov A: SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle. 10:3153–3158. 2011. View Article : Google Scholar : PubMed/NCBI
21	Barneda-Zahonero B and Parra M: Histone deacetylases and cancer. Mol Oncol. 6:579–589. 2012. View Article : Google Scholar : PubMed/NCBI
22	Leiser SF, Fletcher M, Begun A and Kaeberlein M: Life-span extension from hypoxia in Caenorhabditis elegans requires both HIF-1 and DAF-16 and is antagonized by SKN-1. J Gerontol A Biol Sci Med Sci. 68:1135–1144. 2013. View Article : Google Scholar : PubMed/NCBI
23	Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One. 9:e959932014. View Article : Google Scholar : PubMed/NCBI